

BULLETIN FROM Extraordinary GENERAL MEETING OF Q-LINEA AB (PUBL)

The extraordinary general meeting of Q-linea AB (publ) (the “Company”), corp.reg.no 556729-0217, was held on 3 April 2025 in Uppsala, Sweden, at which the shareholders primarily resolved as follows. All resolutions were passed with the required majority.

The general meeting was held at Advokatfirman Lindahl’s premises in Uppsala. For more detailed information on the content of the resolutions, please see the complete notice of the extraordinary general meeting that is available on the Company’s website, www.qlinea.com. Minutes from the extraordinary general meeting will be provided on the mentioned website within two weeks from the day of the meeting.

Amendments to the articles of association

The general meeting resolved, in accordance with the board of directors’ proposal, to amend the articles of association regarding the limits for the share capital in order to implement a reduction of the share capital in the Company.

Reduction of the share capital

The general meeting resolved to reduce the Company’s share capital by SEK 177,931,523.84 to be allocated to unrestricted equity. Consequently, the share capital will be reduced from SEK 222,414,404.80 to SEK 44,482,880.96. As a result, the quota value of the Company’s shares will reduce from SEK 0.05 per share to SEK 0.01 per share.

The reduction is desirable in view of the upcoming exercise of warrants of series TO1 to ensure that the discount of 30 percent against the volume-weighted average price can be applied (however, according to Euroclear Sweden AB’s system, it is technically not possible to have an exercise price below one (1) Swedish öre). An additional reason for the reduction is to achieve a more appropriate share capital for the Company, i.e., to establish a better balance between unrestricted and restricted equity.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

BULLETIN FROM Extraordinary GENERAL MEETING OF Q-LINEA AB (PUBL)